Americredit Second Quarter Earnings Fall

Dendreon says preliminary analysis of prostate cancer vaccine trial inconclusive; Visage plans to buy LAU Systems; plus more of today's stocks in the news

Dendreon Corp (DNDN ) says that preliminary analysis from Phase III trial of Provenge, a vaccine for treatment of prostate cancer, was inconclusive. It continues ongoing Provenge Phase III trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.